.jpg)
Pfizer is set to acquire Seagen for $43 billion and create a new oncology division
13 Dec 2023
In a significant move, Pfizer has announced its anticipation of concluding the $43 billion deal to acquire cancer drug maker Seagen by 16 December 2023.
Moderna sues Pfizer-BioNtech for patent violation
02 Sep 2022
According to Moderna, Pfizer-BioNTech copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged in 2019
Pfizer eyes a market gatecrash as India’s Covid tally mounts
04 May 2021
US pharma giant Pfizer is trying to convince Indian authorities that there is no need for regulatory scrutiny for its corona virus vaccine that added $3.5 billion to its revenue in the first three months of this year, since it is approved by regulatory authorities in the US, Britain, Japan and the WHO, all of which India endorses
Pfizer to acquire cancer drug maker Array Biopharma for $10.6 bn
18 Jun 2019
Array’s Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months, besides revenue from royalty and licensing deals
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Pfizer from Informachine
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
22 Nov 2025
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of care (surgery alone) in cisplatin-ineligible patien
Pfizer Completes Acquisition of Metsera
14 Nov 2025
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer’s Internal Medicine portfolio Positions P
Pfizer Responds to Delaware Chancery Court Ruling
08 Nov 2025
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. f
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
01 Nov 2025
Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach o
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
01 Nov 2025
Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
Pfizer Addresses Proposal for Metsera
30 Oct 2025
Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant marke
Pfizer shares new survival data in non-metastatic prostate cancer
22 Oct 2025
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk
New long-term survival data in advanced lung cancer
22 Oct 2025
BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after approxi
Unprecedented survival data in muscle-invasive bladder cancer
22 Oct 2025
TOKYO AND NEW YORK, October 18, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phas
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
14 Oct 2025
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patien
.webp)
